Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies.

ABSTRACT:

SUBMITTER: Janoudi T 

PROVIDER: S-EPMC11869951 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature